Impact of surveillance for @entity355 on @entity5 stage and survival of @entity1 with XXXX .

@entity1 @entity355 @entity5 @entity420 @entity1141
OBJECTIVE: Endoscopic surveillance for @entity355 ( @entity355 ) is under discussion given the overall low incidence of @entity5 and lack of evidence that it prevents advanced @entity420 ( @entity420 ). The aim of this study was to evaluate the impact of endoscopic @entity355 surveillance on @entity5 stage and survival of @entity1 with @entity5 . DESIGN: 783 @entity1 with @entity355 of at least 2   cm were included in a multicentre prospective cohort and followed during surveillance according to the American College of Gastroenterology guidelines. Cases of high-grade @entity1141 and @entity420 were identified during follow-up. @entity420 staging was performed according to the 7th UICC-AJCC classification. Survival data were collected and crosschecked using death and municipal registries. Data from @entity1 with @entity420 in the general population were obtained from the Dutch @entity5 registry. We compared survival of @entity1 with @entity355 with @entity5 during surveillance with those of @entity1 without @entity5 and @entity1 with @entity420 in the general population. RESULTS: 53 @entity1 with @entity355 developed high-grade @entity1141 or @entity420 during surveillance. Thirty-five (66%) were classified as stage 0, 14 (26%) as stage 1 and 4 (8%) as stage 2. @entity420 was diagnosed at an earlier stage during @entity355 surveillance than in the general population (p<0.001). Survival of @entity1 with @entity355 with @entity5 was not significantly worse than those of @entity1 without @entity5 and similar to survival of @entity1 with stage 0 or stage 1 @entity420 in the general population. CONCLUSIONS: @entity420 is detected at an earlier stage during @entity355 surveillance than in the general population with good survival rates.
